Skip to main
ELAN
ELAN logo

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health has established a strong market presence with Simparica Trio, holding over 50% of the market share, while the anticipated growth of Credelio Quattro from 12.8% to an estimated 16.8% by 2026 indicates robust potential in the companion animal segment. The company’s Advantage Family and Seresto products have demonstrated impressive year-over-year growth of 33% and 28%, respectively, in the third quarter of 2025, reflecting consistent demand and performance improvement. These leading market shares and strong growth metrics position Elanco favorably for continued success in the competitive animal health industry.

Bears say

Elanco Animal Health is facing significant financial challenges as its EBITDA margin has deteriorated despite a 50% increase in revenue, impacting overall profitability. Additionally, concerns regarding refinancing risks have emerged, following Dentsply Sirona's recent bond offering, which could potentially hinder Elanco's earnings growth in 2026. The company’s financial outlook remains precarious, compounded by lower margins and looming refinancing needs, suggesting a negative trajectory in the near term.

ELAN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 8 analysts, ELAN has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.